SLC5A2 and type 2 diabetes mellitus: SGLT2 inhibitors have been used in clinical practice for 10 years, with canagliflozin being the first SGLT2 inhibitor approved by the FDA for the treatment of type 2 diabetes in 2013, followed by dapagliflozin and empagliflozin in 2014, and sotagliflozin and bexagiflozin in 2023.